S
Silence Therapeutics plc (SLN)
NGM – Real Time Price. Currency in USD
6.79
-0.38 (-5.30%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
6.79
-0.38 (-5.30%)
At close: May 12, 2026, 4:00 PM EDT
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
| Name | Position |
|---|---|
| Dr. Marie Wikstrom Lindholm Ph.D. | Chief Scientific Officer |
| Dr. Steven J. Romano M.D. | Executive VP and Chief Research & Development Officer |
| Mr. Curtis Rambaran M.D. | Chief Medical Officer |
| Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | Interim CEO & Chairman of the Board |
| Mr. J.P. Gabriel | Chief Technical Operations Officer |
| Mr. Jaimin B. Shah | SVP & General Counsel |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | sln-20260507.htm |
| 2026-05-07 | 10-Q | sln-20260331.htm |
| 2026-04-29 | ARS | d91508dars.pdf |
| 2026-03-05 | S-8 | d113552ds8.htm |
| 2025-12-22 | 8-K/A | sln-20251214.htm |
| 2025-12-22 | 8-K | sln-20251218.htm |
| 2025-12-15 | 8-K | sln-20251214.htm |
| 2025-11-06 | 8-K | sln-20251106.htm |
| 2025-11-06 | 10-Q | sln-20250930.htm |
| 2025-10-23 | 8-K | sln-20251023.htm |
| Ms. Gem Gokmen Hopkins | Head of IR & Corporate Communications |
| Ms. Rhonda L. Hellums | Executive VP, CFO, Secretary & Executive Director |